Table 1.
Main results of the studies assessing the use of anthracyclines and taxanes-based regimens in patients with breast cancer during pregnancy (with at least 10 patients evaluated).
| Study, Year | Patients Treated with Chemotherapy, N | Type of Regimen | Gestational Age at the Beginning of CT, Weeks | Gestational Age at Delivery, Weeks | Pregnancy Complications and Fetal Outcomes |
|---|---|---|---|---|---|
| Giacalone, 1996 [35] | 29 | FEC, FAC, EC, VEM, VA, FA |
26 | 34.7 | 35% obstetrical complications 10% spontaneous abortion 5% stillbirth No malformations |
| Ring, 2005 [36] | 28 | AC, EC | 20 | 37 | 19% obstetrical complications 4% spontaneous abortion No stillbirths 4% malformations |
| Peccatori, 2009 [37] | 20 | Weekly epirubicin | Not reported | 35 | 10% obstetrical complications No abortion No stillbirths 5% malformations |
| Garcia-Manero, 2009 [38] | 15 | A and Docetaxel, FAC | Not reported | Not reported | 27% obstetrical complications No spontaneous abortion, stillbirths and malformations |
| Cardonick, 2010 [39] | 104 | AC, FAC, EC, FEC, anthracycline followed by taxane | 20.4 | 35.8 | 24% obstetrical complications 5% spontaneous abortion 4% malformations Stillbirths not reported |
| Loibl, 2012 [40] | 197 | A, E, AC, EC, FAC, FEC, anthracycline followed by CMF. Anthracycline followed by taxane | 24 | 37 | 17% obstetrical complications 4% malformations 1% spontaneous abortion and stillbirth |
| Murthy, 2014 [41] | 81 | FAC | Not reported | 37 | 33% obstetrical complications 4% malformations Spontaneous abortion and stillbirths not reported |
| Safi, 2019 [42] | 18 | A, E, Docetaxel, Paclitaxel, | 20 weeks | 35.7 | 12% obstetrical complications No stillbirths and congenital malformations |
| O’Laughlin, 2019 [43] | 50 | AC plus taxane | Not reported | Not reported | Obstetrical complications were not significantly different as compared to patients treated with only anthracycline |
Abbreviations A: Doxorubicin; AC: Doxorubicin, cyclophosphamide; CMF: Cyclophosphamide, methotrexate, 5-fluorouracil; CT: Chemotherapy; E: Epirubicin; EC: Epirubicin, cyclophosphamide; FA: 5-fluorouracil, doxorubicin; FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC: 5-fluorouracil, epirubicin, cyclophosphamide; VA: Vincristine, doxorubicin; VEM: Vincristine, epirubicin, methotrexate.